Items where authors include "van der Heijde, D"

Export as [feed] Atom [feed] RSS
Number of items: 32.

Article

Aletaha, D, Kerschbaumer, A, Kastrati, K et al. (41 more authors) (2022) Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Annals of the Rheumatic Diseases. ISSN 0003-4967

Kroon, FPB, van der Heijde, D, Maxwell, LJ et al. (13 more authors) (2021) Core outcome measurement instrument selection for physical function in hand osteoarthritis using the OMERACT Filter 2.1 process. Seminars in Arthritis and Rheumatism, 51 (6). pp. 1311-1319. ISSN 0049-0172

Mease, PJ, Helliwell, PS orcid.org/0000-0002-4155-9105, Gladman, DD et al. (14 more authors) (2021) Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. The Lancet Rheumatology, 3 (10). e715-e723. ISSN 2665-9913

Costantino, F, Carmona, L, Boers, M et al. (20 more authors) (2021) EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs). Annals of the Rheumatic Diseases. ISSN 0003-4967

Nash, P, Kerschbaumer, A, Dörner, T et al. (26 more authors) (2021) Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the Rheumatic Diseases, 80 (1). pp. 71-87. ISSN 0003-4967

Emery, P orcid.org/0000-0002-7429-8482, Horton, S, Dumitru, RB et al. (5 more authors) (2020) Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial. Annals of the Rheumatic Diseases, 79 (4). pp. 464-471. ISSN 0003-4967

Kiltz, U, Landewé, RBM, van der Heijde, D et al. (21 more authors) (2020) Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. Annals of the Rheumatic Diseases, 79 (2). pp. 193-201. ISSN 0003-4967

Smolen, JS, Landewé, RB, Bijlsma, JWJ et al. (44 more authors) (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases. ISSN 0003-4967

Wittoek, R, Kroon, FPB, Kundakci, B et al. (8 more authors) (2019) Report from the Hand Osteoarthritis Working Group at OMERACT 2018: Update on Core Instrument Set Development. Journal of Rheumatology, 46 (9). ISSN 0315-162X

Otobo, TM, Conaghan, PG orcid.org/0000-0002-3478-5665, Maksymowych, WP et al. (24 more authors) (2019) Preliminary Definitions for Sacroiliac Joint Pathologies in the OMERACT Juvenile Idiopathic Arthritis MRI Score (OMERACT JAMRIS-SIJ). Journal of Rheumatology, 46 (9). pp. 1192-1197. ISSN 0315-162X

van der Heijde, D, Schiff, M, Tanaka, Y et al. (6 more authors) (2019) Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis. RMD Open, 5 (1). e000898. ISSN 2056-5933

Kiltz, U, van der Heijde, D, Boonen, A et al. (24 more authors) (2018) Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. Annals of the Rheumatic Diseases, 77 (9). pp. 1311-1317. ISSN 0003-4967

van der Heijde, D, Dougados, M, Chen, Y-C et al. (10 more authors) (2018) Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open, 4 (1). e000662. ISSN 2056-5933

Coates, LC orcid.org/0000-0002-4756-663X, Gossec, L, Smolen, JS et al. (5 more authors) (2017) New GRAPPA and EULAR recommendations for the management of psoriatic arthritis: process and challenges faced. Rheumatology, 56 (8). pp. 1251-1253. ISSN 1462-0324

Emery, P, Bingham III, CO, Burmester, GR et al. (11 more authors) (2016) Response to: ‘Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!’ by Boers. Annals of the Rheumatic Diseases, 75 (10). e69. ISSN 0003-4967

Conaghan, PG orcid.org/0000-0002-3478-5665, Østergaard, M, Bowes, MA et al. (12 more authors) (2016) Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. Annals of the Rheumatic Diseases, 75 (6). pp. 1024-1033. ISSN 0003-4967

Dale, J, Stirling, A, Zhang, R et al. (8 more authors) (2016) Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial. Annals of the Rheumatic Diseases, 75 (6). pp. 1043-1050. ISSN 0003-4967

Gossec, L, Smolen, JS, Ramiro, S et al. (31 more authors) (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Annals of the Rheumatic Diseases, 75 (3). pp. 499-510. ISSN 0003-4967

Combe, B, Furst, DE, Keystone, EC et al. (5 more authors) (2016) Certolizumab Pegol Remains an Equally Efficacious Treatment of Rheumatoid Arthritis Over a Range of Background Methotrexate Regimens. Arthritis Care and Research, 68 (3). pp. 299-307. ISSN 2151-464X

Ramiro, S, Smolen, JS, Landewé, R et al. (7 more authors) (2016) Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Annals of the Rheumatic Diseases, 75 (3). pp. 490-498. ISSN 0003-4967

Stoffer, MA, Schoels, MM, Smolen, JS et al. (15 more authors) (2016) Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. Annals of the Rheumatic Diseases, 75 (1). pp. 16-22. ISSN 0003-4967

Smolen, JS, Breedveld, FC, Burmester, G et al. (40 more authors) (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the Rheumatic Diseases, 75 (1). pp. 3-15. ISSN 0003-4967

Weinblatt, ME, Fleischmann, R, van Vollenhoven, RF et al. (8 more authors) (2015) Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Arthritis Research and Therapy, 17. 325. ISSN 1478-6354

Gvozdenović, E, Wolterbeek, R, Allaart, CF et al. (13 more authors) (2015) Assessment of global disease activity in RA by patients and physicians: differences across countries in the METEOR Database. JCR: Journal of Clinical Rheumatology, 21 (7). pp. 349-354. ISSN 1076-1608

Mandl, P, Navarro-Compan, V, Terslev, L et al. (19 more authors) (2015) EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. Annals of the Rheumatic Diseases, 74 (7). pp. 1327-1339. ISSN 0003-4967

Kiltz, U, van der Heijde, D, Boonen, A et al. (9 more authors) (2015) Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Annals of the Rheumatic Diseases, 74 (5). pp. 830-835. ISSN 0003-4967

Kiltz, U, van der Heijde, D, Boonen, A et al. (9 more authors) (2014) OP0214 Development of a Health Index in Patients with Ankylosing Spondylitis (ASAS HI) – Final Result of a Global Initiative Based on the ICF Guided by ASAS. Annals of the Rheumatic Diseases, 72. A124-A125. ISSN 0003-4967

Gossec, L, Smolen, JS, Gaujoux-Viala, C et al. (32 more authors) (2012) European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Annals of the Rheumatic Diseases, 71 (1). pp. 4-12. ISSN 0003-4967

Conference or Workshop Item

Mease, P, Helliwell, P orcid.org/0000-0002-4155-9105, Gladman, D et al. (10 more authors) (2022) Effect of Guselkumab a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients With Active PsA: Results From a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years. In: Canadian Rheumatology Association Annual Meeting, 02-05 Feb 2022, Online.

Mease, P, Helliwell, PS orcid.org/0000-0002-4155-9105, Gladman, D et al. (10 more authors) (2021) Effect of Guselkumab (TREMFYA (R)), a Selective IL-23p19 Inhibitor, on Axial-Related Endpoints in Patients with Active PsA: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Mease, P, Helliwell, P orcid.org/0000-0002-4155-9105, Gladman, D et al. (12 more authors) (2021) Efficacy of Guselkumab on Axial-Related Endpoints in Patients with Active Psoriatic Arthritis with Imaging-Confirmed Sacroiliitis. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.

Mease, P, Helliwell, P orcid.org/0000-0002-4155-9105, Gladman, D et al. (15 more authors) (2020) Efficacy of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19 Subunit of IL-23, on Axial-Related Endpoints in Patients with Active PsA with Imaging-Confirmed Sacroiliitis: Week-52 Results from Two Phase 3, Randomized, Double-blind, Placebo-controlled Studies. In: 37º Congresso Brasileiro de Reumatologia, 19-22 Nov 2020, Virtual.

This list was generated on Mon Mar 25 04:04:20 2024 GMT.